{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:59:28Z","timestamp":1787777968909,"version":"build-2784847793"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00520-022-06848-3","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T17:02:56Z","timestamp":1643821376000},"page":"4437-4446","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Vasomotor symptoms in early breast cancer\u2014a \u201creal world\u201d exploration of the patient experience"],"prefix":"10.1007","volume":"30","author":[{"given":"Katherine Marie","family":"Cole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mashari","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Larocque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ardelle","family":"Piper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory R.","family":"Pond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Vandermeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled El","family":"Emam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-6372","authenticated-orcid":false,"given":"Sharon F.","family":"McGee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"issue":"9348","key":"6848_CR1","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/s0140-6736(02)11774-0","volume":"360","author":"V Stearns","year":"2002","unstructured":"Stearns V, Ullmer L, L\u00f3pez JF, Smith Y, Isaacs C, Hayes D (2002) Hot flushes. Lancet 360(9348):1851\u20131861. https:\/\/doi.org\/10.1016\/s0140-6736(02)11774-0","journal-title":"Lancet"},{"key":"6848_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1477-7525-3-47","volume":"3","author":"WH Utian","year":"2005","unstructured":"Utian WH (2005) Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 3:47. https:\/\/doi.org\/10.1186\/1477-7525-3-47","journal-title":"Health Qual Life Outcomes"},{"issue":"Suppl 12B","key":"6848_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.amjmed.2005.09.031","volume":"118","author":"NF Woods","year":"2005","unstructured":"Woods NF, Mitchell ES (2005) Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women\u2019s lives. Am J Med 118(Suppl 12B):14\u201324. https:\/\/doi.org\/10.1016\/j.amjmed.2005.09.031","journal-title":"Am J Med"},{"issue":"9453","key":"6848_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","volume":"365","author":"A Howell","year":"2005","unstructured":"Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, ATAC Trialists\u2019 Group (2005) Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer. Lancet 365(9453):60\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(04)17666-6","journal-title":"Lancet"},{"issue":"3","key":"6848_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/bcr2837","volume":"13","author":"MM Regan","year":"2011","unstructured":"Regan MM, Price KN, Giobbie-Hurder A, Th\u00fcrlimann B, Gelber RD, Group IBCSGaB-C (2011) Interpreting Breast International Group (BIG) 1\u201398: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Res 13(3):209. https:\/\/doi.org\/10.1186\/bcr2837","journal-title":"Breast Cancer Res"},{"issue":"2","key":"6848_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1404037","volume":"371","author":"O Pagani","year":"2014","unstructured":"Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA, TEXT and SOFT Investigators, International Breast Cancer Study Group (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371(2):107\u2013118. https:\/\/doi.org\/10.1056\/NEJMoa1404037","journal-title":"N Engl J Med"},{"issue":"8","key":"6848_CR7","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1200\/JCO.2015.64.3866","volume":"34","author":"PA Ganz","year":"2016","unstructured":"Ganz PA, Petersen L, Bower JE, Crespi CM (2016) Impact of adjuvant endocrine therapy on quality of life and symptoms: observational data over 12 months from the mind-body study. J Clin Oncol 34(8):816\u2013824. https:\/\/doi.org\/10.1200\/JCO.2015.64.3866","journal-title":"J Clin Oncol"},{"issue":"21","key":"6848_CR8","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1200\/JCO.2015.63.8619","volume":"34","author":"JH Chirgwin","year":"2016","unstructured":"Chirgwin JH, Giobbie-Hurder A, Coates AS, Price KN, Ejlertsen B, Debled M, Gelber RD, Goldhirsch A, Smith I, Rabaglio M, Forbes JF, Neven P, L\u00e1ng I, Colleoni M, Th\u00fcrlimann B (2016) Treatment adherence and its impact on disease-free survival in the Breast International Group 1\u201398 trial of tamoxifen and letrozole, alone and in sequence. J Clin Oncol 34(21):2452\u20132459. https:\/\/doi.org\/10.1200\/JCO.2015.63.8619","journal-title":"J Clin Oncol"},{"key":"6848_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.1693","author":"B Yanez","year":"2021","unstructured":"Yanez B, Gray RJ, Sparano JA, Carlos RC, Sadigh G, Garcia SF, Gareen IF, Whelan TJ, Sledge GW, Cella D, Wagner LI (2021) Association of modifiable risk factors with early discontinuation of adjuvant endocrine therapy: a post hoc analysis of a randomized clinical trial. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2021.1693","journal-title":"JAMA Oncol"},{"issue":"27","key":"6848_CR10","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1200\/JCO.2009.25.9655","volume":"28","author":"DL Hershman","year":"2010","unstructured":"Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Gomez SL, Miles S, Neugut AI (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27):4120\u20134128. https:\/\/doi.org\/10.1200\/JCO.2009.25.9655","journal-title":"J Clin Oncol"},{"issue":"11","key":"6848_CR11","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1038\/sj.bjc.6604758","volume":"99","author":"C McCowan","year":"2008","unstructured":"McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99(11):1763\u20131768. https:\/\/doi.org\/10.1038\/sj.bjc.6604758","journal-title":"Br J Cancer"},{"issue":"1","key":"6848_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jamcollsurg.2007.07.015","volume":"206","author":"MU Yood","year":"2008","unstructured":"Yood MU, Owusu C, Buist DS, Geiger AM, Field TS, Thwin SS, Lash TL, Prout MN, Wei F, Quinn VP, Frost FJ, Silliman RA (2008) Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg 206(1):66\u201375. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2007.07.015","journal-title":"J Am Coll Surg"},{"issue":"9869","key":"6848_CR13","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","volume":"381","author":"C Davies","year":"2013","unstructured":"Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, M\u00fcller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urr\u00fatia G, Valentini M, Wang Y, Peto R, Group ATLASAC (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805\u2013816. https:\/\/doi.org\/10.1016\/S0140-6736(12)61963-1","journal-title":"Lancet"},{"issue":"Suppl 1","key":"6848_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10549-007-9698-1","volume":"105","author":"PE Goss","year":"2007","unstructured":"Goss PE (2007) Letrozole in the extended adjuvant setting: MA.17. Breast Cancer Res Treat 105(Suppl 1):45\u201353. https:\/\/doi.org\/10.1007\/s10549-007-9698-1","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 1","key":"6848_CR15","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/s0378-5122(02)00349-3","volume":"44","author":"G Hern\u00e1ndez Mu\u00f1oz","year":"2003","unstructured":"Hern\u00e1ndez Mu\u00f1oz G, Pluchino S (2003) Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas 44(Suppl 1):S59-65. https:\/\/doi.org\/10.1016\/s0378-5122(02)00349-3","journal-title":"Maturitas"},{"issue":"2","key":"6848_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10549-014-2944-4","volume":"145","author":"WY Chen","year":"2014","unstructured":"Chen WY, Giobbie-Hurder A, Gantman K, Savoie J, Scheib R, Parker LM, Schernhammer ES (2014) A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes. Breast Cancer Res Treat 145(2):381\u2013388. https:\/\/doi.org\/10.1007\/s10549-014-2944-4","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"6848_CR17","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.2015.63.2893","volume":"34","author":"G Lesi","year":"2016","unstructured":"Lesi G, Razzini G, Musti MA, Stivanello E, Petrucci C, Benedetti B, Rondini E, Ligabue MB, Scaltriti L, Botti A, Artioli F, Mancuso P, Cardini F, Pandolfi P (2016) Acupuncture as an integrative approach for the treatment of hot flashes in women with breast cancer: a prospective multicenter randomized controlled trial (AcCliMaT). J Clin Oncol 34(15):1795\u20131802. https:\/\/doi.org\/10.1200\/JCO.2015.63.2893","journal-title":"J Clin Oncol"},{"issue":"29","key":"6848_CR18","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1200\/JCO.2010.33.1298","volume":"29","author":"AH Boekhout","year":"2011","unstructured":"Boekhout AH, Vincent AD, Dalesio OB, van den Bosch J, Foekema-T\u00f6ns JH, Adriaansz S, Sprangers S, Nuijen B, Beijnen JH, Schellens JH (2011) Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 29(29):3862\u20133868. https:\/\/doi.org\/10.1200\/JCO.2010.33.1298","journal-title":"J Clin Oncol"},{"issue":"3","key":"6848_CR19","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1200\/JCO.2006.07.5390","volume":"25","author":"CL Loprinzi","year":"2007","unstructured":"Loprinzi CL, Kugler JW, Barton DL, Dueck AC, Tschetter LK, Nelimark RA, Balcueva EP, Burger KN, Novotny PJ, Carlson MD, Duane SF, Corso SW, Johnson DB, Jaslowski AJ (2007) Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. J Clin Oncol 25(3):308\u2013312. https:\/\/doi.org\/10.1200\/JCO.2006.07.5390","journal-title":"J Clin Oncol"},{"issue":"35","key":"6848_CR20","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1200\/JCO.2010.29.9230","volume":"28","author":"L Bordeleau","year":"2010","unstructured":"Bordeleau L, Pritchard KI, Loprinzi CL, Ennis M, Jugovic O, Warr D, Haq R, Goodwin PJ (2010) Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol 28(35):5147\u20135152. https:\/\/doi.org\/10.1200\/JCO.2010.29.9230","journal-title":"J Clin Oncol"},{"issue":"4","key":"6848_CR21","doi-asserted-by":"publisher","first-page":"E86","DOI":"10.1188\/20.ONF.E86-E106","volume":"47","author":"B Hutton","year":"2020","unstructured":"Hutton B, Hersi M, Cheng W, Pratt M, Barbeau P, Mazzarello S, Ahmadzai N, Skidmore B, Morgan SC, Bordeleau L, Ginex PK, Sadeghirad B, Morgan RL, Cole KM, Clemons M (2020) Comparing interventions for management of hot flashes in patients with breast and prostate cancer: a systematic review with meta-analyses. Oncol Nurs Forum 47(4):E86\u2013E106. https:\/\/doi.org\/10.1188\/20.ONF.E86-E106","journal-title":"Oncol Nurs Forum"},{"issue":"1","key":"6848_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3322\/caac.21319","volume":"66","author":"CD Runowicz","year":"2016","unstructured":"Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, Hurria A, Marks LB, LaMonte SJ, Warner E, Lyman GH, Ganz PA (2016) American Cancer Society\/American Society of Clinical Oncology breast cancer survivorship care guideline. CA Cancer J Clin 66(1):43\u201373. https:\/\/doi.org\/10.3322\/caac.21319","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"6848_CR23","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org (2019) Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol 30(8):1194\u20131220. https:\/\/doi.org\/10.1093\/annonc\/mdz173","journal-title":"Ann Oncol"},{"issue":"4","key":"6848_CR24","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.2044-8260.1995.tb01493.x","volume":"34","author":"MS Hunter","year":"1995","unstructured":"Hunter MS, Liao KL (1995) A psychological analysis of menopausal hot flushes. Br J Clin Psychol 34(4):589\u2013599. https:\/\/doi.org\/10.1111\/j.2044-8260.1995.tb01493.x","journal-title":"Br J Clin Psychol"},{"issue":"2","key":"6848_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10549-021-06186-8","volume":"188","author":"KM Cole","year":"2021","unstructured":"Cole KM, Clemons M, Alzahrani M, Larocque G, MacDonald F, Vandermeer L, Hutton B, Piper A, Pond G, McGee S (2021) Developing patient-centred strategies to optimize the management of vasomotor symptoms in breast cancer patients: a survey of health care providers. Breast Cancer Res Treat 188(2):343\u2013350. https:\/\/doi.org\/10.1007\/s10549-021-06186-8","journal-title":"Breast Cancer Res Treat"},{"key":"6848_CR26","doi-asserted-by":"publisher","unstructured":"Cole K, Clemons M, El Emam K, Larocque G, MacDonald F, Vandermeer L, Hutton B, Piper A, Pong G, McGee S (2021) Integrating machine learning models into the management of vasomotor symptoms in breast cancer patients [abstract].\u00a0Abstracts of the 2021 Canadian Association of Medical Oncologists annual meeting. Curr. Oncol 28(3), 2199-2226. https:\/\/doi.org\/10.3390\/curroncol28030204","DOI":"10.3390\/curroncol28030204"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06848-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-06848-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06848-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T03:01:15Z","timestamp":1744167675000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-06848-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["6848"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-06848-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"assertion":[{"value":"21 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Ontario Cancer Research Ethics Board (OCREB).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study, including consent to publish study findings.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"Mark Clemons reports honoraria from Pfizer, outside submitted work. Brian Hutton reports consulting fees from Cornerstone Research and Eversana, outside submitted work. Gregory Pond reports receipt of honorarium from Astra-Zeneca, Merck, Takeda, all outside the submitted work, and has a family member who is an employee of Roche and owns stock in Roche. Khaled El Emam holds equity in Replica Analytics Ltd., a software company spin-off from the University of Ottawa that develops synthetic data generation software. Sharon McGee reports honoraria from Novartis, outside the submitted work. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}